

# Contents

---

Preface	xi
Contributing Authors	xiii
Contents of Volumes 1–5	xix

## **16 / Porphyrins and Phthalocyanines as Photosensitizers and Radiosensitizers** **1**

***Hasrat Ali and Johan E. van Lier***

List of Abbreviations. . . . .	1
I. Introduction . . . . .	2
II. ALA-Based Photosensitizers . . . . .	7
III. Porphyrins. . . . .	11
IV. Purpurins, Benzochlorins, and Porphycenes . . . . .	25
V. Chlorins and Bacteriochlorins. . . . .	30
VI. Expanded Porphyrins . . . . .	44
VII. Core-Modified Porphyrins. . . . .	51
VIII. N-Confused Porphyrins . . . . .	55
IX. Corroles . . . . .	56
X. Subphthalocyanines. . . . .	59
XI. Phthalocyanines. . . . .	61
XII. Naphthalocyanines . . . . .	86
XIII. Radiolabeled Porphyrins and Phthalocyanines. . . . .	90
XIV. Porphyrins and Phthalocyanines as Radiosensitizers. . . . .	95
XV. Acknowledgment. . . . .	99
XVI. References. . . . .	99

## **17 / Bioconjugates of Porphyrins and Related Molecules for Photodynamic Therapy** **121**

***Cristina Alonso and Ross W. Boyle***

List of Abbreviations. . . . .	122
I. Introduction. . . . .	124
II. Bioconjugates Formed by Noncovalent Interactions. . . . .	124

III. Bioconjugates Formed by Covalent Interactions . . . . .	128
A. Sugar-Photosensitizer Conjugates . . . . .	128
B. Conjugation to Polypeptides . . . . .	141
1. Peptide-Photosensitizer Conjugates . . . . .	141
2. Protein-Photosensitizer Conjugates . . . . .	149
C. Conjugation to Antibodies and Antibody Fragments . . . . .	157
1. Conjugation to Monoclonal Antibodies . . . . .	157
2. Conjugation to Antibodies and Antibody Fragments via Linkers . . . . .	164
3. Conjugation to Monoclonal Antibody Fragments . . . . .	170
D. Conjugation to Hormones, Nucleic Acids and Cellular Signaling Species . . . . .	171
IV. Conclusion . . . . .	175
V. Appendix: Conjugation Conditions . . . . .	177
A. Conjugation to Sugars . . . . .	177
B. Conjugation to Peptides and Proteins . . . . .	180
C. Conjugation to Antibodies and Antibody Fragments . . . . .	183
D. Conjugation to Hormones, Nucleic Acids and Cellular Signaling Species . . . . .	186
VI. References . . . . .	187

## **18 / Syntheses of Boronated Porphyrins and Their Application in BNCT 191**

***Maria da Graça H. Vicente and Martha Sibrian-Vazquez***

I. Introduction . . . . .	191
A. The Basis of BNCT . . . . .	192
B. Brief History of Porphyrin-Mediated BNCT . . . . .	194
II. Synthetic Strategies . . . . .	198
A. Porphyrins and Phthalocyanines . . . . .	198
B. Carboranes . . . . .	200
III. Boronated Porphyrins . . . . .	204
A. From Carboranyl-Aldehydes . . . . .	204
1. Porphyrins with up to Four Boron Clusters . . . . .	204
2. Porphyrins of High Boron Content . . . . .	213
B. From Carboranyl-Pyrroles . . . . .	216
C. From Functionalization of Pre-Formed Porphyrin Macrocycles . . . . .	220
IV. Boronated Chlorins . . . . .	231
A. From Boronated Porphyrins . . . . .	231
B. From Functionalization of Chlorophyll-a Derivatives . . . . .	233

V. Boronated Phthalocyanines . . . . .	236
VI. Acknowledgments . . . . .	242
VII. References. . . . .	242

## **19 / Porphyrin-Based Multifunctional Agents for Tumor-Imaging and Photodynamic Therapy (PDT) 249**

***Manivannan Ethirajan, Nayan J. Patel  
and Ravindra K. Pandey***

I. Introduction. . . . .	250
A. Advances in Photodynamic Therapy. . . . .	250
B. Effect of Metalation in PDT . . . . .	257
1. Expanded Porphyrins . . . . .	263
C. Targeted Photosensitizers. . . . .	264
1. Photosensitizer–Carbohydrate Conjugates . . . . .	264
a. STAT-3 Dimerization as a Biomarker in PDT. . . . .	272
2. Photosensitizer–Peptide Conjugates . . . . .	274
D. Activatable Photosensitizers. . . . .	281
E. Photosensitizers for Infectious Diseases . . . . .	284
II. Tumor-Imaging and Therapy . . . . .	286
A. Clinical Applications of Photosensitizers for Fluorescence Imaging and PDT . . . . .	288
B. Conjugates for Fluorescence Imaging and PDT. . . . .	289
C. Conjugates for MR Imaging and PDT . . . . .	294
D. Conjugates for Nuclear Imaging (SPECT/PET) and PDT . . . . .	297
III. Nanoplatfoms for Tumor-Imaging and/or PDT. . . . .	302
A. Nanocrystals. . . . .	306
B. ORMOSIL-Based Nanoparticles. . . . .	307
C. PAA-Based Nanoparticles . . . . .	310
D. Gold Nanoparticles. . . . .	312
IV. Conclusions and Outlook. . . . .	314
V. References. . . . .	315

## **20 / Targeting Strategies for Tetrapyrrole-Based Photodynamic Therapy 325**

***Norbert Jux and Beate Röder***

List of Abbreviations. . . . .	326
I. Introduction. . . . .	328
A. Cellular Targeting . . . . .	329
B. Subcellular Targeting. . . . .	331

II. Cellular Targeting . . . . .	331
A. Active Targeting . . . . .	332
1. Antibodies . . . . .	332
2. Proteins and Peptides . . . . .	343
a. Serum Proteins . . . . .	343
b. Lipoproteins . . . . .	344
c. Transferrin . . . . .	346
d. Other Serum Proteins . . . . .	346
e. Epidermal Growth Factor . . . . .	347
f. Synthetic Peptides . . . . .	348
3. Other Specific Cell Recognition Units . . . . .	351
a. Glycosides . . . . .	351
b. Estrogens . . . . .	353
B. Passive Targeting . . . . .	354
1. Liposomes and Micelles . . . . .	354
2. High-Molecular Weight Targeting Systems . . . . .	366
a. Polymers . . . . .	366
b. Dendrimers . . . . .	369
c. Nanoparticles . . . . .	374
i. Inorganic Nanoparticles . . . . .	376
ii. Biodegradable Nanoparticles . . . . .	380
III. Cell Organelle Targeting . . . . .	385
IV. Targeting of Microorganisms . . . . .	386
A. Active Targeting . . . . .	388
B. Passive Targeting . . . . .	389
V. Outlook . . . . .	393
VI. References . . . . .	394

## **21 / Mechanisms of Cell Death in Photodynamic Therapy      403**

### ***David Kessel***

I. Introduction . . . . .	403
II. Apoptosis as a Death Mode after PDT . . . . .	405
III. Photodamage to Bcl-2 and Bcl-x <sub>L</sub> . . . . .	408
IV. Localization of Photosensitizing Agents . . . . .	410
V. Cellular Targets of PDT: Lysosomes . . . . .	410
VI. Cellular Targets: Plasma Membrane . . . . .	411
VII. The Role of Reactive Oxygen Species (ROS) . . . . .	412
VIII. Apoptosis vs. Necrosis . . . . .	414
IX. Autophagy as a Photodynamic Response . . . . .	414

X. PDT and Membrane Trafficking . . . . .	418
XI. Commentary . . . . .	419
XII. References . . . . .	420

## **22 / Photodynamic Therapy and the Tumor Microenvironment 425**

***Charles J. Gomer, Angela Ferrario, Marian Luna,  
Natalie Rucker, Sam Wong, Ozguncem Bozkulak  
and Frank Xu***

List of Abbreviations . . . . .	425
I. Introduction . . . . .	426
II. PDT and Inhibitors of Cyclooxygenase-2 . . . . .	427
III. PDT and Targeted Anti-Angiogenic Treatment . . . . .	432
IV. PDT Activation of Matrix Metalloproteinases . . . . .	435
V. Protein Kinase B (Akt) Induction by PDT . . . . .	437
VI. Expression of Anti-Apoptotic Survivin Following PDT . . . . .	438
VII. Targeting the 90 kDa Heat Shock Protein Improves PDT . . . . .	439
VIII. Conclusions . . . . .	441
IX. Acknowledgments . . . . .	441
X. References . . . . .	441